Progressive liver failure induced by everolimus for renal cell carcinoma in a 58-year-old male hepatitis B virus carrier

Clinical Journal of Gastroenterology

Volumn 6, Issue 2, 2013, Pages 188-192

  Mizuno, Shinta ^a   Yamagishi, Yoshiyuki ^a   Ebinuma, Hirotoshi ^a   Nakamoto, Nobuhiro ^a   Katahira, Mai ^a   Sasaki, Aya ^a   Sakamoto, Michiie ^a   Suzuki, Hidekazu ^a   Kanai, Takanori ^a   Hibi, Toshifumi ^a  

^a KEIO UNIVERSITY SCHOOL OF MEDICINE   (Japan)

Author keywords

Everolimus; Hepatitis B virus; Immunosuppressive therapy; Liver failure; Nucleoside analogue

Indexed keywords

EVEROLIMUS;

ADULT; ARTICLE; AUTOPSY; CASE REPORT; DISEASE EXACERBATION; DRUG WITHDRAWAL; FATIGUE; FEVER; HEPATITIS B VIRUS; HUMAN; IMMUNOSUPPRESSIVE TREATMENT; INTENSIVE CARE; JAUNDICE; KIDNEY CARCINOMA; LIVER FAILURE; LUNG METASTASIS; MALE; MIDDLE AGED; MYCOSIS; NEPHRECTOMY; NONHUMAN; PRIORITY JOURNAL; VIRUS REACTIVATION;

EID: 84902661548     PISSN: 18657257     EISSN: 18657265     Source Type: Journal    
DOI: 10.1007/s12328-013-0371-4     Document Type: Article

References (14)

1. Chan HY, Grossman AB, Bukowski RM. Everolimus in the treatment of renal cell carcinoma and neuroendocrine tumors. Adv Ther. 2010;27:495-511.
2. Matsuda C, Ito T, Song J, Mizushima T, Tamagawa H, Kai Y, et al. Therapeutic effect of a new immunosuppressive agent, everolimus, on interleukin-10 gene-deficient mice with colitis. Clin Exp Immunol. 2007;128:348-59.
3. Hoofnagle JH. Reactivation of hepatitis B. Hepatology. 2009;49:S156-65.
4. Umemura T, Tanaka E, Kiyosawa K, Kumada H, Japan de novo Hepatitis B Research Group. Mortality secondary to fulminant hepatic failure in patients with prior resolution of hepatitis B virus infection in Japan. Clin Infect Dis. 2008;47:e52-6.
5. Hui CK, Cheung WW, Zhang HY, Au WY, Yueng YH, Leung AY, et al. Kinetics and risk of de novo hepatitis B infection in HBs Ag-negative patients undergoing cytotoxic chemotherapy. Gastroenterogy. 2006;131:59-68.
6. Yeo W, Chan TC, Leung NW, Lam WY, Mo FK, Chu MT, et al. Hepatitis B virus reactivation in lymphoma patients with prior resolved hepatitis B undergoing anticancer therapy with or without rituximab. J Clin Oncol. 2009;27:605-11.
7. Teng CF, Wu HC, Tsai HW, Shiah HS, Huang W, Su IJ. Novel feedback inhibition of surface antigen synthesis by mammalian target of rapamycin (mTOR) signal and its implication for hepatitis B virus tumorigenesis and therapy. Hepatology. 2011;54:1199-207.
8. Manzano-Alonso ML, Castellano-Trtajada G. Reactivation of hepatitis B virus infection after cytotoxic chemotherapy or immunosuppressive therapy. World J Gastroenterol. 2011;17:1531-7.
9. Loomba R, Rowley A, Wesley R, Liang TJ, Hoofnagle JH, Pucino F, et al. Systematic review: the effect of preventive lamivudine on hepatitis B reactivation during chemotherapy. Ann Intern Med. 2008;148:519-28.
10. Lubel JS, Testro AG, Angus PW. Hepatitis B virus reactivation following immunosuppressive therapy: guidelines for prevention and management. Intern Med J. 2007;37:705-12.
11. European Association for the study of the liver. EASL Clinical practice guidelines: management of chronic hepatitis B virus infection. J Hepatol. 2012; [Epub ahead of print].
12. Li HR, Huang JJ, Guo HQ, Zhang X, Xie Y, Zhu HL, et al. Comparison of entecavir and lamivudine in preventing hepatitis B reactivation in lymphoma patients during chemotherapy. J Viral Hepat. 2011;18:877-83.
13. Tsubouchi H, Kumada H, Kiyosawa K. Prevention ofi mmunosuppressive therapy or chemotherapy-induced reactivation of hepatitis B virus infection-Joint report of the Intractable Liver Diseases Study Group of Japan and the Japanese Study Group of the Standard Antiviral Therapy for Viral Hepatitis. Acta Hepatol Jpn. 2009; 50:38-42 (in Japanese).
14. Oketani M, Ido A, Uto H, Tsubouchi H. Prevention of hepatitis B virus reactivation in patients receiving immunosuppressive therapy or chemotherapy. Hepatol Res. 2012;42:627-36.